Background
==========

Postreperfusion cardiac arrest (PRCA) is a dreaded complication of liver transplantation (LT) for both transplant surgeons and anesthesiologists and has been considered the most severe form of postreperfusion syndrome (PRS) with various causes \[[@b1-anntransplant-23-450]--[@b10-anntransplant-23-450]\]. Hyperkalemic preservation solution released from the liver allograft after reperfusion is an acknowledged and well-controlled risk factor for PRCA. However, extended criteria donor (ECD)-related hyperkalemia is usually unheeded in the development of PRCA in LT. Predicting and preventing PRCA during LT using ECD liver grafts remains a challenge. We provide an effective approach for preventing potential PRCA before reperfusion of a high-risk liver graft under the guidance of flushed fluid potassium concentration (FFK) measurements.

Case Report
===========

A 3-year-old boy (height 93 cm, weight 14 kg) with end-stage liver disease (ESLD) from biliary atresia and a pediatric end-stage liver disease score of 7 was listed for LT. Recurrent esophageal variceal hemorrhage, ascites, and splenomegaly had complicated his ESLD. His medical history was significant only for a previous portoenterostomy procedure, and showed no history of congenital heart disease, diabetes mellitus, pneumonia, or acute upper respiratory tract infection. After the patient was transferred to the operating room, routine monitors, including electrocardiogram, pulse oximetry, and non-invasive blood pressure monitors, were established. General anesthesia was induced with titrated midazolam, fentanyl, cisatracurium and propofol and was maintained with sevoflurane in oxygen, remifentanil, and cisatracurium infusions. The trachea was orally intubated without any difficulty, and the patient was mechanically ventilated using pressure control ventilation. Mechanical ventilation was adjusted to maintain the end-tidal carbon dioxide concentration between 35 and 45 mmHg using a 60% oxygen/air mixture. Additional vascular access for invasive monitoring and transfusion was obtained with an arterial line in the left radial artery and a 5.5 French triple-lumen central venous catheter in the right internal jugular vein. The patient was protected from hypothermia by forced-air warming systems (Bair Hugger, 3 M, St. Paul, MN, USA) throughout the procedure. Additionally, a cell saver (CATS, Fresenius Kabi, Bad Homburg, Germany) was used to remove potassium from banked red blood cells (RBCs) and salvaged blood from surgical bleeding.

The donor liver was procured from a 7-year-old girl who died of cerebral trauma through standard donation after brain death process. The graft weighed 623 g and had a normal color, and the cold ischemia time (CIT) was 7 hours upon arrival at our center. However, we considered that localized frostbite might have occurred during transport due to an ice block in the preservation solution, and the right lobe was noted to have a rubbery feel. Because the frostbitten region was relatively small and returned to normal a few minutes later, the operation was cleared to proceed by the surgical team. The recipient hepatectomy was uneventful, and the graft was transplanted using a standard inferior vena cava (IVC) replacement technique without venovenous bypass. The patient remained hemodynamically stable after the portal vein (PV), infrahepatic vena cava (IHVC), and suprahepatic vena cava (SHVC) were clamped. The IHVC anastomosis was initiated when the SHVC anastomosis was completed, and the graft was flushed via the PV with a room temperature albumin solution \[[@b11-anntransplant-23-450]--[@b13-anntransplant-23-450]\]. Unfortunately, the appearance of the flush fluid from the IHVC was slightly turbid ([Figure 1](#f1-anntransplant-23-450){ref-type="fig"}) after flushing with 600 mL of 5% albumin. Consequently, an additional 400 mL of 5% albumin was flushed, and the flush fluid from the graft gradually cleared. Soon afterward, the FFK was measured as 18.8 mmol/L, which likely would have resulted in acute hyperkalemia and PRCA after reperfusion.

After an urgent consult with the surgical and anesthesia teams, the FFK decreased to 9.4 mmol/L after further PV flush with 1200 mL of normal saline. Subsequently, the IHVC anastomosis was completed. During the PV anastomosis, the graft was retrograde-perfused via the IVC with autologous blood by declamping the SHVC and IHVC \[[@b14-anntransplant-23-450],[@b15-anntransplant-23-450]\]. When the PV anastomosis was nearly completed, the perfused blood potassium concentration was measured. The result was 16.6 mmol/L of potassium after perfusion with 100 mL of autologous blood. As a consequence, the PV was not declamped, and antegrade reperfusion \[[@b12-anntransplant-23-450],[@b13-anntransplant-23-450]\] via the PV appeared to be the only effective option to remove the potassium from the graft. After the IHVC and SHVC were clamped again and 3 stitches were removed from the anterior wall of the IHVC, the PV was declamped for reperfusion, and the hyperkalemic blood from the graft was drained from the IHVC and salvaged by the cell saver instead of being returned to the patient's heart. The perfused blood potassium concentration was gradually decreased to 7.5 mmol/L after perfusion with 600 mL of autologous blood ([Table 1](#t1-anntransplant-23-450){ref-type="table"}). The PV was then reclamped, and the anterior wall of the IHVC was resutured. The graft was reperfused again when the residual IHVC anastomosis was completed.

The patient did not experience a PRCA during the immediate reperfusion period. However, the patient's arterial blood pressure gradually decreased from 76/38 mmHg to 62/31 mmHg and was effectively treated with boluses of 3 μg of epinephrine, 20 μg of phenylephrine, and 100 mg of calcium chloride boluses. Simultaneously, the arterial blood gas analysis showed an increase in the serum potassium level from 3.6 to 4.3 mmol/L without a noteworthy widening of the QRS waves, bradycardia, or PRCA. Subsequently, the patient experienced persistent severe hypotension and anuria despite an increase in the dose of norepinephrine from 0.03 to 0.50 μg/kg/min in the late reperfusion period. Therefore, an infusion of pituitrin was started as a consequence of the suspected diagnosis of vasoplegic syndrome. Approximately 5 minutes later, the blood pressure gradually increased from 67/34 mmHg to 101/46 mmHg. Soon afterward, the patient's urine output gradually increased to more than 1 mL/kg/min, and the requirement for norepinephrine was reduced to 0.20 μg/kg/min until the end of the surgery ([Table 2](#t2-anntransplant-23-450){ref-type="table"}).

The remainder of the surgery was completed without any incident. The total duration of the surgery was 435 minutes, and the estimated blood loss was approximately 1100 mL. The patient received 800 mL of packed RBCs, 200 mL of salvaged RBCs, and 400 mL of fresh frozen plasma during the procedure. After surgery, the patient was admitted to the intensive care unit (ICU) without the use of vasopressors and was extubated 1.5 hours later. However, the patient experienced early allograft dysfunction with a temporary increase in the aspartate aminotransferase level to 9339 IU/L. The patient was shifted from the ICU on postoperative day (POD) 5 and was discharged on POD 78. The reason for the prolonged hospitalization was the occurrence of a cytomegalovirus infection. Currently, 16 months postsurgery, the patient is well and shows normal liver function.

Discussion
==========

PRCA is a rare but catastrophic intraoperative complication during LT, with a reported incidence of 0.5--3.2% \[[@b1-anntransplant-23-450]--[@b4-anntransplant-23-450]\]. The occurrence of a PRCA is unpredictable, and the underlying etiology, which includes hyperkalemia, pulmonary embolism, anaphylaxis, intracardiac thrombus, and acute coronary events, is complex and not well understood \[[@b1-anntransplant-23-450]--[@b10-anntransplant-23-450]\]. Recently, considerable attention has been focused on the high incidence of PRCA during LT using ECD liver grafts, and ECD-related hyperkalemia might play a crucial role \[[@b16-anntransplant-23-450],[@b17-anntransplant-23-450]\]. A previous study \[[@b18-anntransplant-23-450]\] demonstrated that high FFK was associated with both severe hypotension and significant arrhythmia during the immediate reperfusion period in LT. In this paper, we report the successful prevention of a case of PRCA with an extremely high FFK when an ECD liver graft was implanted.

Because both PRCA and PRS occur within a few minutes after reperfusion of the donor liver, the causes and manifestations of PRS and PRCA are sometimes confused with one another. PRCA is commonly defined by loss of a spontaneous heartbeat and requires either external or direct cardiac massage after reperfusion of the liver graft \[[@b2-anntransplant-23-450]\], while PRS is typically denoted as cardiovascular collapse following liver graft reperfusion \[[@b19-anntransplant-23-450]\]. The etiologies of PRCA and PRS remain unclear; the latter is a multifactorial complication \[[@b10-anntransplant-23-450]--[@b23-anntransplant-23-450]\], whereas the former is generally caused by a specific cause, such as PRS with and without hyperkalemia and pulmonary embolism \[[@b5-anntransplant-23-450]--[@b10-anntransplant-23-450]\]. Additionally, PRCA is much less common than PRS and is usually regarded as the most serious form of PRS in LT.

Recently, LTs from donation after circulatory death (DCD) liver grafts have increased notably every year \[[@b24-anntransplant-23-450]\]. However, DCD liver grafts are always regarded as marginal donors or ECDs. Other ECDs include liver grafts with an older donor age, a higher donor serum sodium level, a higher degree of steatosis, and a prolonged CIT or warm ischemia time \[[@b20-anntransplant-23-450],[@b22-anntransplant-23-450],[@b23-anntransplant-23-450]\], while a frostbitten liver graft is an infrequent kind of ECD and may result in liver allograft primary nonfunction \[[@b25-anntransplant-23-450]\]. We currently encounter PRS and PRCA more frequently in LT using ECD liver grafts, despite the routine application of the PV flush and speed control reperfusion techniques \[[@b23-anntransplant-23-450],[@b26-anntransplant-23-450]\]. Moreover, we occasionally encounter extremely high serum potassium levels after successful resuscitation of PRS and PRCA \[[@b16-anntransplant-23-450]--[@b18-anntransplant-23-450]\], and the release of intracellular potassium from the damaged hepatocytes of ECD liver grafts are the most likely cause ([Table 3](#t3-anntransplant-23-450){ref-type="table"}).

Hyperkalemia in LT usually results from the transfusion of banked RBCs, which have a potassium concentration of 76 mmol/L after 35 days of cold storage \[[@b27-anntransplant-23-450]\]. This problem has been solved in our center through the use of a cell saver to remove potassium from the banked RBCs. Another important source of potassium might be derived from the University of Wisconsin (UW) preservation solution \[[@b28-anntransplant-23-450]\]. However, graft washout techniques, including the most widely used techniques (PV flush, retrograde reperfusion, and antegrade reperfusion), have been shown to reduce the incidences of PRS and PRCA \[[@b11-anntransplant-23-450]--[@b15-anntransplant-23-450],[@b21-anntransplant-23-450]\]. Importantly, all the washout techniques remove not only the preservation solution but also the necrotic elements of the damaged hepatocytes. A previous study \[[@b11-anntransplant-23-450]\] found that PV flush with 500 mL of 5% albumin is sufficient to remove 90% of the UW preservation solution and to avoid hyperkalemia after reperfusion in the adult population. The type, volume, and temperature of the flush fluid vary based on center-specific experiences. A recent study \[[@b18-anntransplant-23-450]\] found that FFK ≥6.75 mmol/L is associated with significant arrhythmias and persistent severe hypotension in adult LT. The most likely reason for the extremely high FFK is hepatocyte injury of the ECD liver grafts. Therefore, the flush fluid volume might be adjusted when an ECD liver graft is used, and the FFK should be routinely monitored in LT using ECD liver grafts.

Some institutes employ a speed-control reperfusion technique by manually controlling the reperfusion speed, which has been proposed as an effective method for the prevention of PRS and PRCA \[[@b23-anntransplant-23-450],[@b26-anntransplant-23-450]\]. The results are in accordance with the changes in the serum potassium concentration after reperfusion. A transient 2- to 3-fold increase in the potassium level has been reported to occur immediately after reperfusion; the potassium level then returns to normal in 1 to 2 minutes due to uptake by the new liver \[[@b27-anntransplant-23-450],[@b29-anntransplant-23-450]\]. The speed-control reperfusion technique avoids the sudden rise in the serum potassium level, thus preventing PRS and PRCA due to acute hyperkalemia.

Over the past decade, many studies have focused on the treatment of PRCA during LT. Newly developed methods include standard cardiopulmonary resuscitation with external chest compression or direct cardiac massage, external or internal defibrillation, cardiopulmonary bypass, and extracorporeal membrane oxygenation support \[[@b5-anntransplant-23-450]--[@b10-anntransplant-23-450],[@b30-anntransplant-23-450]--[@b32-anntransplant-23-450]\]. However, very few studies have focused on the prediction and prevention of PRCA during LT \[[@b33-anntransplant-23-450]\]. Here, we report the first successfully pretreated case of PRCA due to ECD-related hyperkalemia. To the best of our knowledge, the quality of the donor liver might play a crucial role in the development of PRCA during the reperfusion phase of LT, and the main reason for PRCA during LT using ECD liver grafts might be the hyperkalemic blood released from the damaged hepatocytes during organ retrieval, preservation, and transport.

Conclusions
===========

Our case illustrates that FFK measurement is quite helpful for identifying ECD-related hyperkalemia and should be routinely monitored in LTs using ECD liver grafts.
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###### 

Evolution of the potassium level of the perfused fluid after different treatment strategies.

                      PV flush     PV flush        Retrograde reperfusion   Antegrade reperfusion   Antegrade reperfusion   Antegrade reperfusion
  ------------------- ------------ --------------- ------------------------ ----------------------- ----------------------- -----------------------
  Perfused fluid      5% albumin   Normal saline   Autologous blood         Autologous blood        Autologous blood        Autologous blood
  Volume (mL)         1000         1200            100                      50                      350                     200
  Sampling location   IHVC         IHVC            PV                       IHVC                    IHVC                    IHVC
  K (mmol/L)          18.8         9.4             16.6                     18.5                    11.8                    7.5

PV -- portal vein; IHVC -- infrahepatic vena cava; K -- serum potassium concentration.

###### 

The hemodynamics, temperature, electrolyte, and blood gas measurements during the procedure.

                    Preanhepatic phase   Anhepatic phase   Neohepatic phase                                      
  ----------------- -------------------- ----------------- ------------------ ------ ------ ------ ------ ------ ------
  HR (bpm)          107                  107               114                102    109    109    103    105    109
  MAP (mmHg)        68                   63                61                 62     51     41     45     57     63
  CVP (mmHg)        8                    10                8                  7      6      9      8      10     9
  T (°C)            36.0                 35.6              35.5               34.8   35.4   35.4   35.9   36.0   37.0
  pH                7.38                 7.34              7.40               7.43   7.47   7.32   7.37   7.35   7.38
  PaCO~2~ (mmHg)    36                   35                35                 32     35     37     39     43     43
  PaO~2~ (mmHg)     568                  323               349                520    511    509    349    330    475
  BE (mmol/L)       −3.5                 −6.2              −2.7               −2.7   1.8    −6.4   −2.5   −1.8   0.2
  Na (mmol/L)       134                  137               142                142    146    142    145    146    146
  K (mmol/L)        3.3                  3.7               3.5                3.8    3.6    4.3    2.8    3.4    3.5
  Ca (mmol/L)       1.19                 1.13              1.06               1.21   1.16   1.42   1.04   1.05   1.11
  GLU (mmol/L)      5.1                  3.9               3.9                2.8    3.2    5.2    7.9    7.8    7.5
  LAC (mmol/L)      2.3                  2.5               3.6                4.1    4.3    5.1    6.1    5.2    3.5
  HCT (%)           20                   25                26                 24     22     31     28     25     23
  NE (μg/kg/min)    0.06                 0.03              0.03               0.03   0.20   0.50   0.20   0.20   None
  Pituitrin (U/h)   None                 None              None               None   None   None   1      1      None

BE -- base excess; Ca -- serum calcium concentration; CVP -- central venous pressure; GLU -- blood glucose concentration; HCT -- hematocrit; HR -- heart rate; K -- serum potassium concentration; LAC -- blood lactate concentration; MAP -- mean arterial pressure; Na -- serum sodium concentration; NE -- norepinephrine; PaCO~2~ -- arterial carbon dioxide pressure; PaO~2~ -- arterial oxygen pressure; PV -- portal vein; T -- body temperature.

###### 

Etiology, treatments, and outcomes of reported cases of PRCA during liver transplantation.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Refs.                                              Age/gender                         Diagnosis                    Co-existing diseases             Donor condition                             ECD liver graft      Suspected cause of PRCA   Rise in K/hyperkalemia   Treatments                  Outcome
  -------------------------------------------------- ---------------------------------- ---------------------------- -------------------------------- ------------------------------------------- -------------------- ------------------------- ------------------------ --------------------------- ---------------------
  Shi et al. \[[@b4-anntransplant-23-450]\]          52/NA                              Cirrhosis                    NA                               Deceased                                    NA                   PE                        Yes/No                   CPR (undescribed)           Survived

  49/NA                                              HCC                                NA                           Deceased                         NA                                          NA                   Yes/No                    CPR (undescribed)        Survived                    

  45/NA                                              Hepatitis B cirrhosis              NA                           Deceased                         NA                                          NA                   No/No                     CPR (undescribed)        Death in ICU                

  51/NA                                              HCC, cirrhosis                     NA                           Deceased                         NA                                          Hyperkalemia         Yes/Yes                   CPR (undescribed)        Death in OR                 

  49/NA                                              HCC                                NA                           Deceased                         NA                                          Hyperkalemia         Yes/Yes                   CPR (undescribed)        Death in OR                 

  Aufhauser et al. \[[@b1-anntransplant-23-450]\]    NA/NA                              NA/NA                        3/16 DM, 5/16 PPHTN, 7/16 CRRT   Deceased, 2/16 DCD and 1/16 required ECMO   3/16                 14/16 PRS and 2/16 PE     NA/4/16                  2/16 ECCM+ ED\              Death in OR (3/16)\
                                                                                                                                                                                                                                                                          14/16 TDOCM (7/14 CPB)      Death in ICU (3/16)

  Ulukaya et al. \[[@b7-anntransplant-23-450]\]      66/M                               Alcoholic cirrhosis          ST-T changes                     Deceased, mild steatosis                    Yes                  PRS (hyperkalemia)        NA/NA                    TDOCM                       Survived

  Vannucci et al. \[[@b8-anntransplant-23-450]\]     74/F                               Primary biliary cirrhosis    Hypothyroidism                   Deceased                                    NA                   Hyperkalemia              Yes/Yes                  ECCM, TDCM, ED              Death in ICU

  Tejani et al. \[[@b30-anntransplant-23-450]\]      61/M                               HCC, hepatitis B cirrhosis   No                               Deceased                                    NA                   PRS                       Yes/No                   ECCM, TDOCM, ID, ECMO       Survived

  Lee et al. \[[@b3-anntransplant-23-450]\]          53/F                               Hepatitis B cirrhosis        DM, HRS                          Deceased                                    NA                   PRS (hyperkalemia)        Yes/Yes                  CPR (undescribed)           Survived

  38/M                                               Hepatitis B cirrhosis              No                           Deceased                         NA                                          PRS                  NA/NA                     CPR (undescribed)        Death in ICU                

  32/F                                               HCC, hepatitis B cirrhosis         HE                           Deceased                         NA                                          PRS (hyperkalemia)   Yes/Yes                   CPR (undescribed)        Survived                    

  47/M                                               HCC, hepatitis B cirrhosis         No                           Deceased, mild steatosis         Yes                                         PRS (hyperkalemia)   Yes/Yes                   CPR (undescribed)        Survived                    

  48/M                                               Alcoholic, hepatitis B cirrhosis   HE, HRS                      Deceased, mild steatosis         Yes                                         PRS                  NA/NA                     CPR (undescribed)        Death in ICU                

  Schnüriger et al. \[[@b5-anntransplant-23-450]\]   44/M                               Hepatitis C cirrhosis        NA                               NA                                          NA                   Hyperkalemia              Yes/Yes                  TDOCM, ECMO                 Survived

  63/M                                               Alpha-1 antitrypsin deficiency     NA                           NA                               NA                                          Hyperkalemia         Yes/Yes                   TDOCM, ED or ID          Death in OR                 

  67/M                                               Nonalcoholic steatohepatitis       NA                           NA                               NA                                          Hyperkalemia         Yes/Yes                   TDOCM, ED or ID          Death in OR                 

  64/F                                               Hepatic echinococcosis             NA                           NA                               NA                                          Hyperkalemia         Yes/Yes                   TDOCM                    Death in OR                 

  Andjelić et al. \[[@b10-anntransplant-23-450]\]    54/M                               Hepatitis B cirrhosis        No                               Deceased                                    NA                   Anaphylaxis               NA/NA                    ECCM, ED                    NA

  Wang et al. \[[@b32-anntransplant-23-450]\]        54/M                               Hepatitis B cirrhosis        No                               Living, right lobe                          NA                   VF, MI                    NA/NA                    ECCM, ED, TDOCM, ID, IABP   Death in ICU

  Kim et al. \[[@b9-anntransplant-23-450]\]          61/M                               HCC, hepatitis C cirrhosis   No                               Deceased, 2 h of hypoxemia                  Yes                  Intracardiac thrombus     Yes/No                   TDCM, ED                    Survived

  Shah et al. \[[@b29-anntransplant-23-450]\]        54/M                               Cirrhosis                    No                               Deceased, required ECMO                     Yes                  PRS (hyperkalemia)        Yes/Yes                  ECCM, TDOCM, ED, CPB        Survived
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CPB -- cardiopulmonary bypass; CPR -- cardiopulmonary resuscitation; CRRT -- continuous renal replacement therapy; DM -- diabetes mellitus; ECCM -- external chest cardiac compression; ECD -- expanded criteria donor; ECMO -- extracorporeal membrane oxygenation; ED -- external defibrillation; HCC -- hepatocellular carcinoma; HE -- hepatoencephalopathy; HRS -- hepatorenal syndrome; IABP -- intra-aortic balloon pump; ICU -- Intensive Care Unit; ID -- internal defibrillation; K -- serum potassium concentration; MI -- myocardial infarction; NA -- data not available; OR -- operating room; PE -- pulmonary embolism; PPHT -- portopulmonary hypertension; PRCA -- postreperfusion cardiac arrest; PRS -- postreperfusion syndrome; TDCM -- transdiaphragmatic cardiac compression; TDOCM -- transdiaphragmatic open cardiac massage; VF -- ventricular fibrillation.
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